Tenderwize
Back to tender search

Non-exclusive pharmaceutical discount agreement for Urapidil

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Mar 31, 2028 · 540 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Urapidil (ATC-Code nach WHO: C02CA06)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

40 / 100

Complexity

20 / 100

Risk factors

No minimum purchase quantities; actual revenue uncertain and may be zero.

Buyer can terminate the Open-House process if exclusive agreements are signed, leading to termination of existing non-e...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Mar 31, 2028

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Non-exclusive discount agreements for Urapidil (ATC C02CA06) under § 130a Abs. 8 SGB V
  • Supply of pharmaceutical products to AOK PLUS for patients in Saxony and Thuringia
Show full summary

This notice announces a non-exclusive drug discount agreement (Rabattvereinbarung) for the active substance Urapidil (ATC C02CA06) under an Open-House model. The contracting authority is AOK PLUS for Saxony and Thuringia. No minimum volumes are guaranteed, and quantities depend on demand. The agreement runs until 31 March 2028, with possible early termination if exclusive agreements are concluded. Submission is via the DTVP portal, with a confidentiality requirement. No tender value is published.

Risks

No minimum purchase quantities; actual revenue uncertain and may be zero.

Buyer can terminate the Open-House process if exclusive agreements are signed, leading to termination of existing non-e...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG

Administrative

  • Confidentiality: absolute silence on the content of participation documents
  • Electronic submission via DTVP portal after access request

Requirements may be incomplete.

Award Criteria

Lot 1

Not applicable - Open-House model without award criteria.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive pharmaceutical discount agreement for Urapidil

Non-exclusive framework agreement for Urapidil under an Open-House model. No exclusivity, negotiations, or minimum quantities. All eligible pharmaceutical entrepreneurs may join.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Mar 2026 - Mar 2028

Category

Pharmaceutical products

Award Criteria

Not applicable - Open-House model without award criteria.

Deadline

Deadline Mar 31, 2028

Procurement Details

Publication date
25 Jan 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
56028-2026

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30